Pancreatitis and gallbladder risk with retatrutide

Inflammation of the pancreas, and gallstones brought on by rapid weight loss, are recognised risks of every medicine in retatrutide's class. Retatrutide's trials saw one serious case of pancreatitis and small, symptomless rises in pancreatic enzymes. Both problems announce themselves with tummy pain, which is why the pain matters more than the statistics.

Pancreatitis: what it is

The pancreas sits behind the stomach and makes digestive enzymes and insulin. Acute pancreatitis is a sudden, painful inflammation of it that needs hospital treatment.^[6] The NHS describes the main symptom as pain in the tummy that starts suddenly and does not go away, is severe, sharp or knife-like, and often spreads to the back; it may come with a high temperature, nausea and vomiting, and can feel better leaning forward.^[6]

What the retatrutide trials found

In the Phase 2 trial, one participant had acute pancreatitis serious enough to be recorded as a serious adverse event.^[1] The same trial reported rises in amylase and lipase in some people with no symptoms.^[1] Symptomless enzyme rises are common on this whole drug class; both licensed SmPCs list increased amylase and lipase as side effects.^[3][2] They are a reason for a doctor to check, not proof of harm on their own.

Lilly's Phase 3 announcements have not given pancreatitis figures. Those will come with the full papers, and with thousands of people across the TRIUMPH trials, the published rates will be the first real measure of how often this happens.

Two design facts matter. TRIUMPH-1 excluded anyone who had ever had pancreatitis,^[7] and the Phase 2 trial excluded people with a history of pancreatitis or symptomatic gallbladder disease.^[8] Whatever the trial rates turn out to be, they will not describe people who have had pancreatitis before.

What the class warnings say

Retatrutide is not licensed, so it has no SmPC. Its closest licensed relatives do, and their warnings are the best available guide to what a regulator would say. Both the Wegovy and Mounjaro SmPCs state that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome; that neither drug has been studied in people with a history of pancreatitis; and that people should be told the symptoms and stop the medicine if pancreatitis is suspected.^[2][3]

In the UK, the MHRA and Genomics England launched a Yellow Card Biobank study in June 2025 recruiting people who developed acute pancreatitis on a GLP-1 medicine, to find out whether genetic make-up raises the risk.^[5] That study exists because the question is unanswered for the licensed drugs, let alone for retatrutide.

Gallstones and gallbladder inflammation

Gallstones are hard lumps that form in the gallbladder, the small organ that stores bile. Most cause no symptoms. When one blocks a duct it causes sudden, intense pain in the upper right or centre of the tummy, and can lead to inflammation of the gallbladder (cholecystitis) or the pancreas.^[4]

Losing weight quickly is itself a risk factor for gallstones, whatever the method; the NHS lists rapid weight loss alongside obesity, age and being female.^[4] On top of that, both licensed SmPCs list gallstones and cholecystitis as side effects, and the Mounjaro SmPC notes that in its weight-management trials gallbladder events were more common in people who lost more weight.^[3][2] Retatrutide produces faster and larger weight loss than either, so there is no reason to expect it to be gentler on the gallbladder. Retatrutide-specific figures are not yet published.

Symptoms and what to do

The NHS says to ask for an urgent GP appointment or contact NHS 111 if you get sudden, severe tummy pain that does not go away or keeps coming back, or comes with a high temperature or feeling hot, cold or shivery. It says to call 999 or go to A&E if sudden, severe tummy pain is spreading to your back, or comes with bloating that will not settle, a fast heartbeat, difficulty breathing, or discoloured skin around the tummy.^[6]

Whichever service you contact, tell them what you injected, when, and that it was an unlicensed product. A clinician who knows that will check the right things, including pancreatic enzymes and liver tests. The talking to your GP page covers that conversation, and any suspected reaction can be sent to the MHRA through the Yellow Card scheme.

Trial product versus what is sold online

Everything above about rates comes from trials of a known, pure product at a known dose. A vial sold online may contain more retatrutide than its label says, less, or something else; and it may carry bacteria or other contaminants that can cause their own abdominal illness. Severe tummy pain after injecting an unlicensed product could be pancreatitis, a gallstone, an infection, or liver injury, which is covered on the liver and kidney page. Only a clinician with blood tests can tell which. Unlicensed products carry unknown extra risks on top of the drug's own.